The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)

• Published in: Blood 2020-11, Vol.136 (Supplement 1), p.30-31
• Main Authors: Ho, Phoebe Joy, Moore, Elizabeth M., Wellard, Cameron, Quach, Hang, Blacklock, Hilary, Harrison, Simon J, McDonald, Emma-Jane, McQuilten, Zoe, Wood, Erica M., Mollee, Peter, Spencer, Andrew
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2020-141511

BACKGROUND For many years active myeloma (MM) was defined by 4 CRAB criteria: hyperCalcemia, Renal impairment, Anaemia, Bone lesions. In 2014, 3 additional biomarkers that were associated with ≥70% chance of activation to symptomatic myeloma (CRAB) within 2 years were adopted as myeloma defining events: clonal bone marrow (BM) plasma cell (PC) percentage ≥60%, involved: uninvolved serum free light chain ratio (SFLCR) ≥100, and >1 focal lesion on MRI - the SLiM criteria (SixtyLightchainMRI). We assessed the application of these criteria in a real-life population to determine their impact on clinical practice and treatment outcomes. METHODS AND AIMS We evaluated clinical characteristics, treatment & outcomes of pts registered in the Australian & New Zealand Myeloma Registry (MRDR) from 2013 to 2018, comparing pts diagnosed with active MM by CRAB (n=1686) vs SLiM (n=132) criteria. RESULTS Patient & Disease characteristics: In 132 SLiM pts, 58 had BMPC≥60%, 48 SFLCR≥100 and 26 were known to have both, nil had MRI lesions. CRAB pts included a higher proportion with advanced stage ISS-3 (35.6% vs 10.7%, p